Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DA6NG5
|
|||
Drug Name |
Nimacimab
|
|||
Synonyms |
Namacizumab
Click to Show/Hide
|
|||
Drug Type |
Antibody
|
|||
Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
Company |
Bird Rock Bio
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Antagonist | [2] |
KEGG Pathway | Rap1 signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Retrograde endocannabinoid signaling | ||||
Panther Pathway | Endogenous cannabinoid signaling | |||
Pathway Interaction Database | N-cadherin signaling events | |||
Reactome | Class A/1 (Rhodopsin-like receptors) | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Small Ligand GPCRs | ||||
BDNF signaling pathway | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03900325) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Bird Rock Bio. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.